Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
03. Dezember 2024 08:30 ET
|
Eterna Therapeutics
Eterna Launches Research to Evaluate its Lead iMSC Therapy Candidate’s Ability to Induce and Modulate Antitumor Immunity in Ovarian and Breast Models
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
25. November 2024 08:30 ET
|
Eterna Therapeutics
Eterna Therapeutics Announces $1 Million Stock Repurchase Program
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
14. November 2024 08:30 ET
|
Eterna Therapeutics
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
30. Oktober 2024 08:30 ET
|
Eterna Therapeutics
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
17. Oktober 2024 08:00 ET
|
Eterna Therapeutics
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license...
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
10. Mai 2024 08:00 ET
|
Eterna Therapeutics
Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
08. Mai 2024 09:31 ET
|
Eterna Therapeutics
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
07. Mai 2024 08:00 ET
|
Eterna Therapeutics
Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
07. Mai 2024 08:00 ET
|
Eterna Therapeutics
Eterna Therapeutics to present a poster at ASGCT on the Development of a mRNA-Engineered iPSC Line, via Targeted Insertion of HLA-E at the B2M Locus
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
20. Februar 2024 08:30 ET
|
Eterna Therapeutics
Eterna Therapeutics (ERNA) Announces the Appointment of Peter Cicala, JD, to its Board of Directors